期刊
CELLULAR SIGNALLING
卷 82, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2021.109954
关键词
Adenosine receptor; Allostery; Biased agonism; Drug discovery; G protein-coupled receptor
类别
资金
- National Heart Foundation of Australia Future Leader fellowship [101857]
- Australian Research Training Program (RTP) scholarship
- National Health and Medical Research Council (NHMRC) of Australia [1147291]
- National Health and Medical Research Council of Australia [1147291] Funding Source: NHMRC
Research has shown that utilizing biased agonism of adenosine receptor ligands can help avoid adverse effects and play a positive role in therapy.
Adenosine modulates many aspects of human physiology and pathophysiology through binding to the adenosine family of G protein-coupled receptors, which are comprised of four subtypes, the A(1)R, A(2A)R, A(2B)R and A(3)R. Modulation of adenosine receptor function by exogenous agonists, antagonists and allosteric modulators can be beneficial for a number of conditions including cardiovascular disease, Parkinson's disease, and cancer. Unfortunately, many preclinical drug candidates targeting adenosine receptors have failed in clinical trials due to limited efficacy and/or severe on-target undesired effects. To overcome the key barriers typically encountered when transitioning adenosine receptor ligands into the clinic, research efforts have focussed on exploiting the phenomenon of biased agonism. Biased agonism provides the opportunity to develop ligands that favour therapeutic signalling pathways, whilst avoiding signalling associated with on-target undesired effects. Recent studies have begun to define the structure-function relationships that underpin adenosine receptor biased agonism and establish how this phenomenon can be harnessed therapeutically. In this review we describe the recent advancements made towards achieving therapeutically relevant biased agonism at adenosine receptors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据